Germany Pharmaceuticals Market size is estimated to be $38.9 billion in 2019, growing at a CAGR of 6.7% during the forecast period 2020-2025. Increasing population along with the increase in the number of people suffering from various types of diseases including cardiovascular diseases, cancer, diabetes and others is a vital factor driving Germany Pharmaceuticals Market in the upcoming years. Moreover, according to a recent article published by Annals of Global Health cardiovascular diseases remains the leading cause of death in Europe accounting for 45% of all deaths. More than 4 million Europeans die every year from CVD, primarily from coronary artery disease and stroke. Furthermore, the upsurge in the number of people suffering from various diseases has increase the opportunities of various pharmaceuticals company to develop various drugs for their treatment. Besides, this the increased funding by various companies is another vital factor contributing to its market growth. For instance, Biontech, Curevac bagged $745m in German funding for Covid-19 vaccine.

Germany Pharmaceuticals Market Segment Analysis – By Drug Class

By Drug Class the Germany Pharmaceuticals Market is segmented into Anti-Cancer, Anti-Diabetes, Anti-Rheumatics, Vaccines and others. Anti-Cancer segment held the largest market share in the year 2019 owing to the rising number of patient suffering from different types of cancer and the increasing demand of different types of drugs for its cure. For instance, according to a recent article published by International Journals of Cancer breast cancer is the most common cancer-related cause of death of women in Germany. In 2018 about 72,000 incident cases were expected and about 19,000 women died from breast cancer in 2016. Also, anti-diabetes segment is projected to witness growth at fastest CAGR of 7.13% in forecast period 2020-2025. The increasing number of patients suffering from diabetes and their will to adopt different types of drugs or treatment for its cure is a vital factor contributing to its market growth. Moreover, according a recent article published in July 2018, German pharma major Boehringer Ingelheim clocked a 43.7% CAGR in the domestic anti-diabetes therapy segment in the past three years, catapulting to the eighth spot from the 15th position in 2016.

Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=19490

Report Price: $ 4500 (Single User License)

Germany Pharmaceuticals Market Segment Analysis – By Application

By Application the Germany Pharmaceuticals Market is segmented into Oncology, Infectious Diseases, Cardiovascular Disease, Central Nervous System Disorder and Others. Oncology segment held the largest market share in the year 2019 owing to the increasing number of oncology drugs developed in that region. For instance, in December 2019 German pharmaceutical companies launched 25 new drugs including ten against cancer in 2019. Also, infectious disease segment is projected to witness growth at fastest CAGR of XX% in forecast period 2020-2025. Increase in the prevalence of infectious diseases such as HIV/AIDs, hepatitis, STDs and the adoption of an appropriate drugs is a major factor driving the Germany Pharmaceuticals Market in the upcoming years. Moreover, according to World Health Organization in 2017 nearly 160,000 people were newly diagnosed with HIV in the European region.

Germany Pharmaceuticals Market Segment Analysis – By Geography

Germany contributed to the largest market share owing to the presence of large dominant players in the region including Bayer, Boehringer Ingelheim, Merck KGAA, Fresenius Kabi and Stada. Growing population along with the increase in the number of people suffering various types of disease, improved healthcare structure, increasing healthcare expenditure and the increasing awareness among consumers regarding early diagnosis and treatment is a vital factor upsurging its market growth. Besides, this the presence of various government organization is another vital factor fueling its market growth. For instance, The European Medicines Agency works closely with the national competent authorities of member states of the European Union and the European Economic Area responsible for human medicines.

Germany Pharmaceuticals Market Drivers

Large pool of People Suffering From Lung Cancer

Large pool of people suffering from lung cancer is a significant factor driving the Germany Pharmaceuticals market during the forecast period 2020-2025. Moreover, according to Robert Koch Institut in 2016 approximately 21,500 women and 36,000 men were diagnosed with malignant tumors of the lung and 16,481 women and 29,324 men died of the disease. Therefore, increase in the number of people suffering from lung cancer has pushed Pharmaceuticals Company to develop a wide range of drugs and therapy for its treatment which in turn is fueling its market growth.

Increasing Funding From Government Organization

Increasing funding from government organizations is driving the Germany Pharmaceuticals Market during the forecast period 2020-2025. For instance, in November 2016 the government of Germany has announced its support for the development of new treatment to combat tuberculosis (TB). Germany’s Federal Ministry of Education and Research has committed euro 10 million for over five years to TB alliance, facilitated by KfW development bank. This grant is part of a slate of support intended to spur product development to fight neglected disease.

Download Sample Report @ https://www.industryarc.com/pdfdownload.php?id=19490

Germany Pharmaceuticals Market Challenges

High-Cost Raw Materials

High Cost of raw material including API to manufacture drugs serves as a major setback for the growth of the Germany Pharmaceuticals Market during the forecast period 2020-2025. Owing to its high cost the small companies are unable to purchase it which in turn is restraining its market during the forecast period 2020-2025.

Germany Pharmaceuticals Market Industry Outlook

Product Launches, Merger & Acquisition, joint ventures and R&D activities are key strategies adopted by the players in Germany Pharmaceuticals Market. Germany Pharmaceuticals Market top 10 are Bayer, Boehringer Ingelheim, Merck KGAA, Fresenius Kabi, Stada, Pfizer, Novartis AG, Abbott, Teva Pharmaceutical Industries Ltd and Abbvie Inc.,

Germany Pharmaceuticals Market Developments:

August 2019: Telix Pharmaceuticals a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted biopharmaceuticals entered into a collaboration and option agreement with German Cancer Research Center for image-guided prostate surgery.

Key Takeaways

Anti-Cancer segment held the largest market share in the year 2019 owing to the rising number of patient suffering from different types of cancer and the increasing demand of different types of drugs for its cure.

Oncology segment held the largest market share in the year 2019 owing to the increasing number of oncology drugs developed in that region.

Germany contributed to the largest market share of owing to the presence of large dominant players in the region including Bayer, Boehringer Ingelheim, Merck KGAA, Fresenius Kabi and Stada.

Large pool of people suffering from lung cancer is a significant factor driving the Germany Pharmaceuticals market during the forecast period 2020-2025.

Related Reports :

A. Ethical Pharmaceuticals Market

https://www.industryarc.com/Report/15835/ethical-pharmaceuticals-market.html

B. Pharmaceutical Packaging Market

https://www.industryarc.com/Report/5339/Pharmaceutical-Packaging-Market-Research-Report.html

For more Lifesciences and Healthcare related reports, please click here

About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.